Objective:To systematically evaluate the clinical effect and safety of Buzhong Yiqi tang for myasthenia gravis.Methods:Searched for literature from January 2007 to September 2017 in Chinese National Knowledge Infrastructure(CNKI),Wanfang Data Knowledge Service Platform,VIP Chinese Journal Database(VIP),Chinese Biological Medical Disc(CBM),PubMed,Cochrane Library and Science Citation Index(SCI)Database.Selected clinical randomized controlled trials,adapted the assessment method of risk of bias recommended by Cochrane to evaluate risk of bias of patients who met the inclusion criteria and extracted the data.The meta-analysis was conducted via Review Manager 5.3 software.Results:Thirteen clinical studies were included,including 795 cases totally.The result showed that when compared the therapy of Buzhong Yiqi tang combined with routine western medicine for myasthenia gravis with that of simple routine western medicine,the effective rate in the treatment group was superior to that in the control group,the difference being significant[OR=3.36,95%CI(2.35,4.81),P < 0.000 01];the recurrence rate in the treatment group was lower than that in the control group,the difference being significant[OR=0.11,95%CI(0.04,0.34),P < 0.000 1];the incidence of adverse reactions in the treatment group was lower than that in the control group,the difference being significant[OR=0.24,95%CI(0.10,0.54),P=0.000 6].Conclusion:The therapy of Buzhong Yiqi tang combined with routine western medicine for myasthenia gravis can effectively improve clinical symptoms of patients and improve safety of medication.However,due to the low quality of selected literature,the clinical effect and safety of Buzhong Yiqi tang for myasthenia gravis need to be verified through the literature of higher quality and larger sample as well as randomized controlled doubled-blinded clinical trials.